ANAPTYSBIO, INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($4.3m) ($30.1m) ($61.7m) ($97.3m) ($19.9m) ($57.8m) ($128.7m) ($163.6m) ($145.2m) ($13.2m)
Net Income (Loss) Available to Common Stockholders, Basic ($4.3m) ($30.1m) ($61.7m) ($97.3m)
Depreciation, Depletion and Amortization $233k $183k $315k $514k $559k $619k $675k $652k $606k $559k
Share-based Payment Arrangement, Noncash Expense $1.2m $4.4m $33.2m $34.0m $36.1m
Payment, Tax Withholding, Share-based Payment Arrangement $7.5m $1.5m
Share-based Payment Arrangement, Expense $34.0m $36.1m
Gain (Loss) on Disposition of Property Plant Equipment ($1k) $0 $0 $100k $0
Income Tax Expense (Benefit) $0 $0 ($192k) ($152k) $0 $0 $24k ($4k) $3k $164k
Other Nonoperating Income (Expense) ($147k) $229k ($159k) $1k ($11k) $37k $12k ($2k) $14k $5.4m
Additional Financial Items
Proceeds from Stock Options Exercised $31k $979k $2.9m $3.0m $496k $2.1m $11.3m $1.8m $5.3m $12.9m
Foreign Currency Transaction Gain (Loss), before Tax ($100k) $200k
General and Administrative Expense $4.3m $9.3m $15.5m $16.1m $18.9m $21.5m $36.6m $41.9m $42.4m $50.7m
Investment Income, Interest $127k $1.6m
Nonoperating Income (Expense) ($1.2m) ($1.3m) $4.9m $9.9m $3.9m ($982k) ($13.5m) $788k ($30.3m) ($61.0m)
Operating Expenses $19.7m $38.8m $71.7m $115.4m $98.9m $120.0m $125.4m $181.6m $206.2m $186.7m
Revenue from Contract with Customer, Including Assessed Tax $5.0m
Unrealized Gain (Loss) on Investments $1.2m ($493k) $2.5m $10.5m $10.3m $4.7m
Net Cash Provided by (Used in) Operating Activities ($9.0m) ($19.4m) ($48.5m) ($69.5m) ($14.2m) ($45.9m) ($73.6m) ($120.8m) ($135.3m) $19.7m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $50k $290k $1.1m $805k $569k $1.4m $358k $807k $358k $87k
Net Cash Provided by (Used in) Investing Activities ($50k) ($243.1m) ($142.5m) $131.4m $94.5m $38.8m ($394.8m) $144.8m $95.4m $228.0m
Cash flows from financing activities:
Proceeds from Issuance of Common Stock $0 $292.5m $227.5m $0 $0 $2.6m $11.8m $2.5m $6.5m $14.3m
Payments for Repurchase of Common Stock $1k $0 $0 $0 $0 $50.0m $456k $68.6m
Net Cash Provided by (Used in) Financing Activities $8.6m $292.5m $223.4m ($4.5m) ($879k) $252.3m $44.0m ($59.3m) $127.1m ($132.6m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $32.4m $57.4m $79.4m $245.2m ($424.4m) ($35.3m) $87.1m $115.1m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $51.3m $81.2m $113.7m $171.1m $250.5m $495.7m $71.3m $36.0m $123.1m $238.2m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $1.0m $424k $4k $0 $0 $42.1m $80.0m